Clinical Trials Browser

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT03161522 2025-10-23

Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer

Phase 2 Recruiting

100 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT06687876 2025-07-10

MEMENTO

Phase 2 Recruiting

14 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms

NCT04114136 2025-02-10

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Phase 2 Recruiting

72 enrolled

DermatologicGastrointestinalHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Melanoma

NCT05476796 2024-10-24

LOGICAN

Phase 2 Recruiting

118 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Neoplasm Metastasis, Recurrence

NCT05713838 2024-09-19

Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

Phase 2 Recruiting

32 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT05177133 2024-08-02

AuspiCiOus

Phase 2 Recruiting

25 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Microsatellite Instability

NCT04018872 2021-11-04

Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer

Phase 2 Recruiting

78 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms

Clinical Trials

Obeticholic Acid for Prevention in Barrett's Esophagus

OLIGOMETS

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

TNT-OES-2

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

GRACIE

PSI-Immune

Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer

MEMENTO

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

LOGICAN

Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

AuspiCiOus

Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer